Novo CEO gives key update on when its next obesity drug could launch

TheStreet · Mwangi Enos · 2026-11-06 00:03 UTC

Mike Doustdar said Novo is "already in production mode" for CagriSema.

I know that for people trying to lose weight, the process can be exhausting. Diet plans, gym memberships, expensive meal-replacement subscriptions, and months of trying to stay consistent can take a real toll.

And when some begin looking for medical help, a whole growing range of obesity drugs becomes a new worry in the room. The question is no longer how to lose weight, but which treatment is worth considering.

Novo Nordisk is about to add another option, as CEO Mike Doustdar told Bloomberg on Nov. 4. The drug is CagriSema, a once-weekly injection.

Read the full story at TheStreet · All coverage of this story